Search results

Skip to results

Type

Status

Last updated

Showing 1 to 3 of 3 results for mavacamten

  1. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913

  2. Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

    In development [GID-TA11664] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. First treatment to target heart condition set to benefit

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.

    News
    Last updated
    22 January 2024